Cargando…
Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics
Chronic active Epstein-Barr virus disease (CAEBV) is a systemic lymphoproliferative disorder that is closely linked to Epstein-Barr virus (EBV) infection. The clinical course and severity of CAEBV can vary, and in some cases, it can progress to overt lymphoma, which is characterized by extranodal na...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149821/ https://www.ncbi.nlm.nih.gov/pubmed/37138889 http://dx.doi.org/10.3389/fimmu.2023.1172307 |
_version_ | 1785035228450914304 |
---|---|
author | Wang, Yao Zhang, Minan Xue, Qingfeng Zhou, Huan Chen, Jie Wang, Hong Zhang, Yaping Shi, Wenyu |
author_facet | Wang, Yao Zhang, Minan Xue, Qingfeng Zhou, Huan Chen, Jie Wang, Hong Zhang, Yaping Shi, Wenyu |
author_sort | Wang, Yao |
collection | PubMed |
description | Chronic active Epstein-Barr virus disease (CAEBV) is a systemic lymphoproliferative disorder that is closely linked to Epstein-Barr virus (EBV) infection. The clinical course and severity of CAEBV can vary, and in some cases, it can progress to overt lymphoma, which is characterized by extranodal natural killer/T-cell lymphoma (ENKTL) and has a poor clinical outcome. Although anti-programmed cell death protein-1 (PD-1) therapy has shown effectiveness in some patients with EBV-associated disease, it has been less successful in others, and the exact mechanism of action of PD-1 inhibitor therapy in these diseases remains unclear. In this report, we describe a patient who was diagnosed with ENKTL secondary to CAEBV and experienced rapid disease progression accompanied by hyperinflammation after receiving PD-1 inhibitor therapy. Single-cell RNA sequencing revealed a significant increase in the patient’s lymphocyte count, especially in natural killer cells, with increased activity following PD-1 inhibitor therapy. This case raises questions about the efficacy and safety of PD-1 inhibitor therapy in patients with EBV-associated diseases. |
format | Online Article Text |
id | pubmed-10149821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101498212023-05-02 Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics Wang, Yao Zhang, Minan Xue, Qingfeng Zhou, Huan Chen, Jie Wang, Hong Zhang, Yaping Shi, Wenyu Front Immunol Immunology Chronic active Epstein-Barr virus disease (CAEBV) is a systemic lymphoproliferative disorder that is closely linked to Epstein-Barr virus (EBV) infection. The clinical course and severity of CAEBV can vary, and in some cases, it can progress to overt lymphoma, which is characterized by extranodal natural killer/T-cell lymphoma (ENKTL) and has a poor clinical outcome. Although anti-programmed cell death protein-1 (PD-1) therapy has shown effectiveness in some patients with EBV-associated disease, it has been less successful in others, and the exact mechanism of action of PD-1 inhibitor therapy in these diseases remains unclear. In this report, we describe a patient who was diagnosed with ENKTL secondary to CAEBV and experienced rapid disease progression accompanied by hyperinflammation after receiving PD-1 inhibitor therapy. Single-cell RNA sequencing revealed a significant increase in the patient’s lymphocyte count, especially in natural killer cells, with increased activity following PD-1 inhibitor therapy. This case raises questions about the efficacy and safety of PD-1 inhibitor therapy in patients with EBV-associated diseases. Frontiers Media S.A. 2023-04-17 /pmc/articles/PMC10149821/ /pubmed/37138889 http://dx.doi.org/10.3389/fimmu.2023.1172307 Text en Copyright © 2023 Wang, Zhang, Xue, Zhou, Chen, Wang, Zhang and Shi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Yao Zhang, Minan Xue, Qingfeng Zhou, Huan Chen, Jie Wang, Hong Zhang, Yaping Shi, Wenyu Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics |
title | Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics |
title_full | Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics |
title_fullStr | Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics |
title_full_unstemmed | Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics |
title_short | Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics |
title_sort | case report: immune modulation after pd-1 inhibitor therapy in a patient with extranodal nk/t-cell lymphoma secondary to chronic active epstein-barr virus disease unveiled by single-cell transcriptomics |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149821/ https://www.ncbi.nlm.nih.gov/pubmed/37138889 http://dx.doi.org/10.3389/fimmu.2023.1172307 |
work_keys_str_mv | AT wangyao casereportimmunemodulationafterpd1inhibitortherapyinapatientwithextranodalnktcelllymphomasecondarytochronicactiveepsteinbarrvirusdiseaseunveiledbysinglecelltranscriptomics AT zhangminan casereportimmunemodulationafterpd1inhibitortherapyinapatientwithextranodalnktcelllymphomasecondarytochronicactiveepsteinbarrvirusdiseaseunveiledbysinglecelltranscriptomics AT xueqingfeng casereportimmunemodulationafterpd1inhibitortherapyinapatientwithextranodalnktcelllymphomasecondarytochronicactiveepsteinbarrvirusdiseaseunveiledbysinglecelltranscriptomics AT zhouhuan casereportimmunemodulationafterpd1inhibitortherapyinapatientwithextranodalnktcelllymphomasecondarytochronicactiveepsteinbarrvirusdiseaseunveiledbysinglecelltranscriptomics AT chenjie casereportimmunemodulationafterpd1inhibitortherapyinapatientwithextranodalnktcelllymphomasecondarytochronicactiveepsteinbarrvirusdiseaseunveiledbysinglecelltranscriptomics AT wanghong casereportimmunemodulationafterpd1inhibitortherapyinapatientwithextranodalnktcelllymphomasecondarytochronicactiveepsteinbarrvirusdiseaseunveiledbysinglecelltranscriptomics AT zhangyaping casereportimmunemodulationafterpd1inhibitortherapyinapatientwithextranodalnktcelllymphomasecondarytochronicactiveepsteinbarrvirusdiseaseunveiledbysinglecelltranscriptomics AT shiwenyu casereportimmunemodulationafterpd1inhibitortherapyinapatientwithextranodalnktcelllymphomasecondarytochronicactiveepsteinbarrvirusdiseaseunveiledbysinglecelltranscriptomics |